The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | BrECADD regimen is superior in treating advanced HL: results from the HD21 trial
In this presentation, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the results of the HD21 trial (NCT02661503), which aimed to compare the superiority of progression-free survival (PFS) between the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) and BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) regimens in patients with advanced stage classical Hodgkin lymphoma (cHL). This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
